USFDAJul 23, 2026, 08:37 AM
Inhibikase IKT-001 Granted FDA Orphan Drug Designation for PAH
AI Summary
Inhibikase Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead product candidate, IKT-001, for the treatment of Pulmonary Arterial Hypertension (PAH). This designation provides significant potential benefits, including tax credits on qualified clinical trial costs, exemption from certain FDA user fees, and the potential for seven years of market exclusivity upon regulatory approval. The company highlighted IKT-001's pre-clinical data showing improvements in PAH markers and lower GI toxicity compared to imatinib mesylate.
Key Highlights
- FDA granted Orphan Drug Designation (ODD) to IKT-001 for Pulmonary Arterial Hypertension (PAH).
- PAH affects approximately 50,000 people in the United States.
- ODD provides potential incentives including tax credits on clinical trial costs and exemption from FDA user fees.
- The designation also offers potential for seven years of market exclusivity upon regulatory approval.
- IKT-001 is a prodrug of imatinib mesylate, targeting abnormal proliferation of vascular cells in the lung.
- Pre-clinical data showed IKT-001 improved pulmonary vascular and hemodynamic markers of PAH.
- IKT-001 demonstrated a lower potential for GI toxicity compared to imatinib mesylate.
Price Impact
More from IKT